CD4 and neoplasm: These novel CD4+CD69+FOXP3− Tregs accounted for the vast majority of tumor‐infiltrating Tregs compared with FOXP3+ Tregs and could suppress the CD4+ T‐cell response mainly through mTGF‐β1,145, 146 which was correlated with tumor progression.